Skip to main content

Dr. Christopher B. Benton, M.D.

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Medical school
Baylor College of Medicine (2005)
Years since graduation
21
In the NPI registry since
2009
Medicare patients seen, 2024
665

Licensed in Texas since 2010, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2005Medical school: Baylor College of Medicine
  • 2009Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    CO license DR.0062478 (first issued 2019; active)
  • Internal Medicine Physician
    TX license BP10023108 · TX license N5566 (first issued 2010; canc non-renewal)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
665
Services billed
174,457
Patients’ average age
74
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, darbepoetin alfa, 1 microgram (non-esrd use)35,08530
Injection, luspatercept-aamt, 0.25 mg21,40011
Injection, iron sucrose, 1 mg20,70040
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)16,32021
Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram13,32018
Injection, pembrolizumab, 1 mg12,40018
Injection, fosaprepitant, 1 mg11,25030
Injection, azacitidine, 1 mg6,40011
Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units3,34012
Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg2,46011

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Jakafi (ruxolitinib phosphate)343
Warfarin Sodium
Other prescribers in Englewood, CO
189
Eliquis (apixaban)
Other prescribers in Englewood, CO
187
Xarelto (rivaroxaban)
Other prescribers in Englewood, CO
169
Valacyclovir (valacyclovir hcl)
Other prescribers in Englewood, CO
106
Hydroxyurea
Other prescribers in Englewood, CO
79
Revlimid (lenalidomide)60
Ojjaara (momelotinib dihydrochloride)58
Venclexta (venetoclax)52
Inqovi (decitabine/cedazuridine)43

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 22 companies reported 112 payments worth $118,372 in total to this clinician.

By type
Compensation for services other than consulting (speaking, faculty)$62,622
Consulting Fee$47,662
Travel and Lodging$5,208
Food and Beverage$2,880

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
May 8, 2025Alexion Pharmaceuticals, Inc.
May 8, 2025
Consulting Fee$9,920
Jan 24, 2025E.r. Squibb & Sons, L.l.c.
Jan 24, 2025
Consulting Fee$7,640
Mar 12, 2025Geron Corporation
Mar 12, 2025
Compensation for services other than consulting (speaking, faculty)
RYTELO · MYELODYSPLASTIC SYNDROME
$5,760
Sep 4, 2025E.r. Squibb & Sons, L.l.c.
Sep 4, 2025
Compensation for services other than consulting (speaking, faculty)
REBLOZYL · Hematology
$5,460
May 1, 2025E.r. Squibb & Sons, L.l.c.
May 1, 2025
Compensation for services other than consulting (speaking, faculty)
REBLOZYL · Hematology
$4,550
May 29, 2025Novartis Pharmaceuticals Corporation
May 29, 2025
Consulting Fee$4,200
Oct 22, 2025Geron Corporation
Oct 22, 2025
Compensation for services other than consulting (speaking, faculty)
RYTELO · MYELODYSPLASTIC SYNDROME
$4,160
Jul 24, 2025Sobi, Inc
Jul 24, 2025
Compensation for services other than consulting (speaking, faculty)
Vonjo · Hematology/Oncology
$3,850
Oct 30, 2025Sobi, Inc
Oct 30, 2025
Compensation for services other than consulting (speaking, faculty)
Vonjo · Hematology/Oncology
$3,850
May 5, 2025E.r. Squibb & Sons, L.l.c.
May 5, 2025
Compensation for services other than consulting (speaking, faculty)
REBLOZYL · Hematology
$3,640
All 56 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 4, 2025GlaxoSmithKline, LLC.
Dec 4, 2025
Compensation for services other than consulting (speaking, faculty)
OJJAARA · ONCOLOGY
$1,088
Nov 11, 2025Incyte Corporation
Nov 11, 2025
Compensation for services other than consulting (speaking, faculty)
Jakafi · Hematology/Oncology
$2,740
Oct 30, 2025Sobi, Inc
Oct 30, 2025
Compensation for services other than consulting (speaking, faculty)
Vonjo · Hematology/Oncology
$3,850
Oct 22, 2025Geron Corporation
Oct 22, 2025
Compensation for services other than consulting (speaking, faculty)
RYTELO · MYELODYSPLASTIC SYNDROME
$4,160
Oct 17, 2025GlaxoSmithKline, LLC.
Oct 17, 2025
Compensation for services other than consulting (speaking, faculty)
OJJAARA · ONCOLOGY
$1,450
Oct 8, 2025GlaxoSmithKline, LLC.
Oct 8, 2025
Compensation for services other than consulting (speaking, faculty)
OJJAARA · ONCOLOGY
$2,900
Oct 2, 2025GlaxoSmithKline, LLC.
Oct 2, 2025
Travel and Lodging
OJJAARA · ONCOLOGY · travel to Albuquerque, NM · in-kind
$482
Oct 2, 2025GlaxoSmithKline, LLC.
Oct 2, 2025
Travel and Lodging
OJJAARA · ONCOLOGY · travel to Albuquerque, NM · in-kind
$299
Oct 1, 2025Incyte Corporation
Oct 1, 2025
Compensation for services other than consulting (speaking, faculty)
Jakafi · Hematology/Oncology
$2,055
Sep 25, 2025Sobi, Inc
Sep 25, 2025
Compensation for services other than consulting (speaking, faculty)$3,080
Sep 25, 2025Geron Corporation
Sep 25, 2025
Travel and Lodging
RYTELO · MYELODYSPLASTIC SYNDROME · travel to COLORADO SPRINGS, CO · in-kind
$1,054
Sep 24, 2025Incyte Corporation
Sep 24, 2025
Compensation for services other than consulting (speaking, faculty)
Jakafi · Hematology/Oncology
$2,055
Sep 4, 2025E.r. Squibb & Sons, L.l.c.
Sep 4, 2025
Compensation for services other than consulting (speaking, faculty)
REBLOZYL · Hematology
$5,460
Sep 4, 2025AbbVie Inc.
Sep 4, 2025
Consulting Fee
VENCLEXTA · ONCOLOGY
$525
Sep 2, 2025E.r. Squibb & Sons, L.l.c.
Sep 2, 2025
Consulting Fee$955
Aug 21, 2025E.r. Squibb & Sons, L.l.c.
Aug 21, 2025
Travel and Lodging
REBLOZYL · Hematology · travel to Pueblo, CO
$761
Aug 16, 2025Syndax Pharmaceuticals, Inc.
Aug 16, 2025
Consulting Fee
REVUFORJ · HEMATOLOGY-ONCOLOGY
$3,475
Aug 16, 2025Syndax Pharmaceuticals, Inc.
Aug 16, 2025
Travel and Lodging
REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to SCOTTSDALE, AZ · in-kind
$282
Aug 16, 2025Syndax Pharmaceuticals, Inc.
Aug 16, 2025
Travel and Lodging
REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to SCOTTSDALE, AZ · in-kind
$141
Aug 16, 2025Syndax Pharmaceuticals, Inc.
Aug 16, 2025
Travel and Lodging
REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to SCOTTSDALE, AZ · in-kind
$41.51
Jul 25, 2025Syndax Pharmaceuticals, Inc.
Jul 25, 2025
Compensation for services other than consulting (speaking, faculty)
REVUFORJ · HEMATOLOGY-ONCOLOGY
Company’s descriptionBranded Speaker Training
$900
Jul 24, 2025Sobi, Inc
Jul 24, 2025
Compensation for services other than consulting (speaking, faculty)
Vonjo · Hematology/Oncology
$3,850
Jul 17, 2025Novartis Pharmaceuticals Corporation
Jul 17, 2025
Consulting Fee
SCEMBLIX · Oncology
$1,400
Jul 15, 2025Genzyme Corporation
Jul 15, 2025
Consulting Fee$3,360
Jul 14, 2025Novartis Pharmaceuticals Corporation
Jul 14, 2025
Consulting Fee
SCEMBLIX · Oncology
$1,400
Jun 27, 2025Novartis Pharmaceuticals Corporation
Jun 27, 2025
Consulting Fee$2,800
Jun 17, 2025GlaxoSmithKline, LLC.
Jun 17, 2025
Compensation for services other than consulting (speaking, faculty)
OJJAARA · ONCOLOGY
$2,900
Jun 10, 2025GlaxoSmithKline, LLC.
Jun 10, 2025
Compensation for services other than consulting (speaking, faculty)
OJJAARA · ONCOLOGY
$2,900
Jun 10, 2025Incyte Corporation
Jun 10, 2025
Compensation for services other than consulting (speaking, faculty)
Jakafi · Hematology/Oncology
$2,055
Jun 6, 2025Incyte Corporation
Jun 6, 2025
Compensation for services other than consulting (speaking, faculty)
Jakafi · Hematology/Oncology
$343
May 29, 2025Novartis Pharmaceuticals Corporation
May 29, 2025
Consulting Fee$4,200
May 22, 2025Sobi, Inc
May 22, 2025
Consulting Fee
Vonjo · Hematology/Oncology
$1,155
May 15, 2025E.r. Squibb & Sons, L.l.c.
May 15, 2025
Consulting Fee$1,194
May 8, 2025Alexion Pharmaceuticals, Inc.
May 8, 2025
Consulting Fee$9,920
May 6, 2025Syndax Pharmaceuticals, Inc.
May 6, 2025
Compensation for services other than consulting (speaking, faculty)$1,500
May 5, 2025E.r. Squibb & Sons, L.l.c.
May 5, 2025
Compensation for services other than consulting (speaking, faculty)
REBLOZYL · Hematology
$3,640
May 1, 2025E.r. Squibb & Sons, L.l.c.
May 1, 2025
Compensation for services other than consulting (speaking, faculty)
REBLOZYL · Hematology
$4,550
Apr 25, 2025Alexion Pharmaceuticals, Inc.
Apr 25, 2025
Travel and Lodging
travel to Tamoa, FL · in-kind
Company’s descriptionConsulting Expenses
$309
Apr 25, 2025Alexion Pharmaceuticals, Inc.
Apr 25, 2025
Travel and Lodging
travel to Denver, CO
Company’s descriptionConsulting Expenses
$58.00
Apr 25, 2025Alexion Pharmaceuticals, Inc.
Apr 25, 2025
Travel and Lodging
travel to Tampa, FL · in-kind
Company’s descriptionConsulting Expenses
$43.42
Apr 7, 2025GlaxoSmithKline, LLC.
Apr 7, 2025
Consulting Fee
OJJAARA · ONCOLOGY
$2,800
Mar 19, 2025Taiho Oncology, Inc.
Mar 19, 2025
Consulting Fee
INQOVI · Oncology
$2,100
Mar 12, 2025Geron Corporation
Mar 12, 2025
Compensation for services other than consulting (speaking, faculty)
RYTELO · MYELODYSPLASTIC SYNDROME
$5,760
Mar 6, 2025AbbVie Inc.
Mar 6, 2025
Consulting Fee
VENCLEXTA · ONCOLOGY
$600
Feb 28, 2025GlaxoSmithKline, LLC.
Feb 28, 2025
Compensation for services other than consulting (speaking, faculty)
OJJAARA · ONCOLOGY
$1,452
Feb 25, 2025E.r. Squibb & Sons, L.l.c.
Feb 25, 2025
Compensation for services other than consulting (speaking, faculty)
REBLOZYL · Hematology
$3,185
Feb 21, 2025Amgen Inc.
Feb 21, 2025
Compensation for services other than consulting (speaking, faculty)
BLINCYTO · Oncology
$750
Feb 6, 2025Geron Corporation
Feb 6, 2025
Travel and Lodging
RYTELO · MYELODYSPLASTIC SYNDROME · travel to TUCSON, AZ · in-kind
$835
Feb 6, 2025Geron Corporation
Feb 6, 2025
Travel and Lodging
RYTELO · MYELODYSPLASTIC SYNDROME · travel to TUCSON, AZ · in-kind
$384
Feb 6, 2025Geron Corporation
Feb 6, 2025
Travel and Lodging
RYTELO · MYELODYSPLASTIC SYNDROME · travel to TUCSON, AZ · in-kind
$279
Feb 6, 2025Geron Corporation
Feb 6, 2025
Travel and Lodging
RYTELO · MYELODYSPLASTIC SYNDROME · travel to TUCSON, AZ · in-kind
$239
Jan 31, 2025Syndax Pharmaceuticals, Inc.
Jan 31, 2025
Consulting Fee$1,200
Jan 24, 2025E.r. Squibb & Sons, L.l.c.
Jan 24, 2025
Consulting Fee$7,640
Jan 24, 2025E.r. Squibb & Sons, L.l.c.
Jan 24, 2025
Consulting Fee$1,038
Jan 13, 2025Syndax Pharmaceuticals, Inc.
Jan 13, 2025
Consulting Fee$1,200
Jan 1, 2025Novartis Pharmaceuticals Corporation
Jan 1, 2025
Consulting Fee
SCEMBLIX · Oncology
$700

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Colorado →

Industry-funded research

Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $212,196 in research payments for these studies, mostly to the institutions running them.

  • A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis
    Karyopharm Therapeutics Inc.
  • A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia
    Takeda Pharmaceuticals U.S.A., Inc.
  • A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications
    Karyopharm Therapeutics Inc.
  • Study name not reported
    Pharmaessentia USA Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Englewood

Sources

NPI registry (CMS NPPES, November 2026; record last updated September 6, 2023), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1255667655. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.